Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Submitted by Anonymous on

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious adverse events (0%)No dose-limiting toxicities observed.No treatment discontinuations due to adverse events...

Hh and EGFR-Ras signaling promote distinct steps of tumor progression in the Drosophila follicle epithelium

Submitted by Anonymous on

Controlled signaling activity is vital for normal tissue homeostasis and oncogenic signaling activation facilitates tumorigenesis. Here, we combine single-cell transcriptomics with in-depth genetic and imaging analysis to investigate the role of the EGFR-Ras and Hedgehog signaling pathways in homeostasis of...

The differential roles of Giardia duodenalis-secreted tenascins in inducing intestinal epithelial cell apoptosis and the attributed EGFR-STAT3 axis regulation

Submitted by Anonymous on

Abstract Giardia duodenalis is an important extracellular protozoan parasite of the gut responsible for waterborne diarrhea in human and nonhuman animals worldwide. Giardia trophozoites express and secrete excretory-secretory proteins (ESPs) affecting structural, cellular, and soluble components of the host small...

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort

Submitted by Anonymous on

AbstractBackground Comprehensive genomic analysis and optimal treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) G719X + S768I co-mutations remain limited. This study aimed to elucidate the genetic landscape and the clinical effectiveness of EGFR tyrosine kinase...

Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand

Submitted by Anonymous on

Abstract Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. Although EGFR-TKIs can cause various adverse events (AEs), their profiles have not been fully elucidated...

Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System

Submitted by Anonymous on

PerspectiveEfforts toward Equity Share on Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital SystemAuthors: Angelica Bocour, M.P.H., Erin Lewis, M.D., Silas Lee, M.S., and Leo G. Eisenstein, M.D. https://orcid.org/0000-0003-4714-6990Author Info & AffiliationsPublished...

Subscribe to Newsfeed